A Medical Decision Support System That Learns



Best Practices Winner: Children’s Hospital of Philadelphia
Project: Pediatric Knowledgebase
Category: Judges’ Prize

By Allison Proffitt

August 6, 2009
| “Wouldn’t it be great if we could [build a system] that ‘learned’ every time a patient walked in the door?” asks Jeff Barrett, director, Pediatric Pharmacology Research Unit, at the Children’s Hospital of Philadelphia, or CHOP. He’s envisioning a solution that’s part electronic medical record, part drug encyclopedia, and part patient chart. The result was the Pediatric Knowledgebase (PKB).

PKB was designed to meet many of the challenges of pediatric pharmacotherapy including, 1) provide dosing guidance consistent with formulary standard of care, 2) examine patient pharmacotherapeutic indices with respect to agent performance relative to controls derived from the hospital data warehouse, 3) explore treatment-diagnoses-drug correlation in conjunction with use and 4) educate physicians on clinical pharmacologic principles specific to population and drug combinations of interest.”

The PKB integrates the hospital’s medical records with drug-specific decision support generated by clinical pharmacology experts and clinical caregivers and predictive models generated by CHOP’s pharmacometric and informatics team. Forecasting tools evaluate dosing scenarios to be explored via a user friendly interface that front-ends a pediatric population-based PK/PD model. The result is therapeutic drug monitoring for children that uses patient data to help predict outcomes and inform clinical decisions in individual patients.

“Drug monitoring with a decision support system is sort of novel,” says Barrett. “There are services for [drug monitoring], but it’s disconnected from the patient’s history.” The PKB solution, however, is closely tied to personal data. The interface currently has drug dashboard prototypes for methotrexate (chemotherapeutic agent), tacrolimus (used to prevent organ rejection) and vancomycin (antibiotic) that are being evaluated clinically. “The dashboards are based on one drug, but they’re designed to go across drugs as well and monitor drug interactions,” explains Barrett.

Building the system was a multidisciplinary project, Barrett says. “We have an extremely varied group of individuals [involved in the project], and it’s the primary reason we’ve been able to get this far: pharmacometrics, clinical pharmacology, clinical/medical roles, programming/information technology, bioinformatics, data management and data integration.”

The project demanded that both the IT and the clinical communities be able to “look behind the curtain,” says Barrett. “We are integrated with the hospital’s information management system, [and]… we’ve got investment from the care givers. We knew that unless they were part of the process and actually designed what these systems looked like, [it wouldn’t work]. ”

In order for PKB to grow, partnerships have to expand outside of CHOP. The drug dashboards will eventually be populated with data through external collaborations. CHOP is part of the Pediatric Pharmacology Research Unit Network of children’s hospitals, Barrett says, and the PKB will receive data from several member hospitals. “This environment accumulates clinical outcomes including adverse events in a HIPAA-compliant informatics system,” the entry states.

Full Production
At CHOP, the production version of the PKB is waiting for the hospital’s new EMR system to be fully rolled out. It is  planned for piloting at Cincinnati Children’s Hospital and LeBonheur Children’s Medical Center in Memphis. The results have been good with “emphasis on clinical outcomes including reduced medication errors and length of hospital stay have been used to demonstrate the ROI for individual dashboards.”

The PKB was designed to work with various EMR systems, though customization will be required for each implementation. “It’s web based, and we want to see it go globally… first within the U.S., but there is some very strong expertise particularly in Europe and in the Netherlands especially. They’ve been doing [therapeutic drug monitoring] a lot longer.”

In the meantime, the team is “trying to create a consortium around this so that we have other folks participate in the development of this system. Cincinnati Children’s has already committed to going down this path with us,” Barrett says.

“We have an external advisory board that helps us plan for the IT challenges across the globe.” Specifically, the PKB plans to make use of technology solutions that have broad appeal, “in particular SAS and the JMP product.” Also in the works: “We’re planning for a PKB-Lite version that allows people to upload data into a larger system, meant to accommodate a smaller outpatient setting.”

“This has been such a blessing for us,” says Barrett of winning the Best Practices award. “As we’re putting together the documentation for the consortium and identifying what the PKB is and seeks to do, we [now] have some external validation that this is a project that’s been well thought out and has the right sorts of teams interested. It will improve the visibility of our efforts and we’re looking at this to kind of kick this over the top.


This article also appeared in the July-August 2009 issue of Bio-IT World Magazine.
Subscriptions are free for qualifying individuals. Apply today.

Click here to login and leave a comment.  

1 Comments

  • Avatar

    Hello, I was wondering: Does this system involve a Prolog (or Datalog in general) part/module? If not, has it been considered?

    Kind Regards
    Samuel Lampa

Add Comment

Text Only 2000 character limit

Page 1 of 1



White Papers & Special Reports

sgi - whp 1
Turning Genomics Data into Practical Insight
Sponsored by SGI

With worldwide sequencing capacity approaching 13 quadrillion DNA bases annually turning genomics data into knowledge is a true computational challenge. Read this paper and learn how the SGI UV coherent shared memory platform can:  

  • Speed results time while cost competitively tackling the most difficult computational problems across all omics disciplines. 
  • Push performance by scaling to extraordinary levels, up to 256 sockets (2,560 cores, 4,096 threads) per single system (one OS image). 

Provide support for up to 16TB of coherent shared memory in a single system image enabling extreme efficiency across a wide range of compute demands. 



accerlys-logo_2012_wh
New Complimentary Market Survey…
Collaborations and Communications Within Drug Discovery Research
Sponsored by Accelrys
This survey was conducted by the Cambridge Healthtech Media Group in January, 2012. It was sponsored by Accelrys related to their HEOS initiative to gather valid information around externalizing collaborative research while improving communications in the cloud. With 310 qualified industry respondents the survey findings reveal useful usage and trends patterns.  An insightful follow-on discussion and webinar related to this survey, and the HEOS by Scynexis SaaS portal is also available on the Bio-IT World website for complementary viewing.
 


Job Openings

tessella logo 
Scientific Software Engineer
Boston MA
$70,000 to $95,000
 

Tessella delivers software engineering and consulting services to leading pharmaceutical and biotech companies. We are recruiting Software Engineersto work with skilled bioinformaticians and scientists to identify business needs and recommend and develop technical solutions. Applicants require BS, MS or PhD in bioinformatics, biology or chemistry and 2+ years of software development in either: Java, C#, C++, C or VB.NET. 

Apply at http://jobs.tessella.com   

 

oxford nanopore logo 


 Early Access Collaborations Managers
Oxford Nanopore Technologies is developing a novel technology, GridIONTM for the direct, electronic analysis of DNA/RNA and other analytes.  As the system approaches the market, we are building a team of technically knowledgeable, highly motivated candidates with excellent customer service and facilitation skills to join our company as Collaboration Managers.  This is a unique opportunity to work with world-leading genomics customers throughout the early adoption phase of a new generation of DNA sequencing technology.. This is a facilitative, enabling role with responsibility for managing technology development collaborations with key customers at leading genomics institutions.  It will include long term management of the collaboration plan and milestones and associated meetings and documentation. Click here to find out more and apply   

Oxford Nanopore's GridION technology, VP, Sales and Marketing Oxford Nanopore Technologies is a fast-moving technology company that is developing a novel electronic molecular analysis technology. The technology is adaptable for the analysis of DNA/RNA, proteins, chemicals and other molecules.  It is therefore suitable for use in a variety of markets including scientific research and clinical applications.  As the technology approaches the market, Oxford Nanopore is seeking a visionary VP of sales and marketing to join the senior team.  The candidate will embrace the opportunities afforded by entering the market with a truly disruptive technology that has the potential to expand the number of users and the variety of applications in each target market.  This is a rare opportunity to influence the commercial strategy at an early phase of its commercial lifetime, in a well funded company.  Oxford Nanopore welcomes applications from candidates with a track record of high-level strategic commercial  leadership, who wish to apply a fresh approach to existing markets.  Experience in Life Sciences/DNA sequencing is central to this role, however we will consider your application if you have experience of disruptive technologies in other related industries.  We are particularly interested in candidates with strong expertise in the use of digital technologies for sales and marketing of scientific/technical products.  Click to  Apply  


 

For reprints and/or copyright permission, please contact  Tim McLucas, (781) 972-1342, tmclucas@healthtech.com .